Robert McWhirter Medx Health Corp. MDX-X BUY Aug 25, 2017

This company's product is truly revolutionary, because it looks millimetres below the skin’s surface to actually see what is going on. They take a picture, send it on a secure basis to a dermatologist, who then sees the situation. A year ago, they retooled their laser therapy device, and that is selling quite well. They are working on some improved software to make it easier on a "plug-and-play" basis for the actual melanoma detection device. A great product. The company needs sales of about $1.8 million to break even, and they have $9 million of tax loss carry forward. His expectation is that by Q3 of 2018, they will be profitable. He owns warrants on this.

This company sells technology that looks with light 2 mm below the skin to determine whether you have melanoma, moles or otherwise. Skin cancer is a growing problem and this is a good product for it. The company is gaining customers in Spanish-speaking countries (Spain, Mexico, etc.)

He thinks there is good opportunity for this medical device manufacturer with the arrival of a new CEO. Note: His wife works as a consultant for this company.

They have a new President and CEO. They released a new web site. They replace needles for dental work with laser. On the innovative side, their Durham product gives totally secure examination of a mole with results in 72 hours. The long awaited approval of the devices in Mexico is expected soon. There are expected global partnerships. He thinks there are really good opportunities for them.